Charles Schwab
BDSX icon

Charles Schwab’s Biodesix BDSX Stock Holding History

Charles Schwab’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,031
Closed -$12.9K – 3501
2025
Q1 		$12.9K Hold
1,031
– – ﹤0.01% 3471
2024
Q4 		$31.6K Hold
1,031
– – ﹤0.01% 3466
2024
Q3 		$36.7K Hold
1,031
– – ﹤0.01% 3443
2024
Q2 		$31.6K Hold
1,031
– – ﹤0.01% 3559
2024
Q1 		$29.5K Hold
1,031
– – ﹤0.01% 3415
2023
Q4 		$37.9K Hold
1,031
– – ﹤0.01% 3430
2023
Q3 		$34K Hold
1,031
– – ﹤0.01% 3447
2023
Q2 		$25.4K Hold
1,031
– – ﹤0.01% 3527
2023
Q1 		$38.4K Buy
+1,031
New +$42.3K ﹤0.01% 3391
2022
Q2 		– Sell
-1,705
Closed -$58K – 3549
2022
Q1 		$58K Buy
1,705
+135
+9% +$8.82K ﹤0.01% 3507
2021
Q4 		$167K Hold
1,570
– – ﹤0.01% 3384
2021
Q3 		$259K Sell
1,570
-497
-24% -$94.3K ﹤0.01% 3292
2021
Q2 		$547K Buy
2,067
+910
+79% +$286K ﹤0.01% 3140
2021
Q1 		$470K Buy
1,157
+134
+13% +$59.9K ﹤0.01% 3101
2020
Q4 		$413K Buy
+1,023
New +$319K ﹤0.01% 3050

Other funds holding BDSX

TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Charles Schwab's BDSX Position: Q2 2025 in Review

Charles Schwab sold out of Biodesix (BDSX) in Q2 2025, closing a stake of 1,031 shares — an estimated $12.9K sold.

Charles Schwab first reported a position in BDSX in Q4 2020 and held it in 15 quarters. The position peaked at $547K in Q2 2021. 40 funds tracked by Wall St. Rank hold BDSX as of Q2 2025.

  • Charles Schwab reported no remaining Biodesix position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 1,031 Biodesix shares in Q2 2025, an estimated $12.9K.
  • Charles Schwab first reported a position in Biodesix in Q4 2020 and held it in 15 quarters.
  • Charles Schwab's Biodesix position peaked at $547K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Biodesix as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.